| 查看: 582 | 回复: 2 | |||
lijizhi79木虫 (小有名气)
|
[交流]
GlaxoSmithKline and Novartis, starring players in a Big Pharma deal bonanza 已有2人参与
|
|
While the chattering classes were chattering about a potential Pfizer-AstraZeneca merger yesterday, three other drug giants were putting the finishing touches on a big announcement. Novartis ($NVS), whose strategic review has been making headlines for almost a year, agreed to swap some assets with GlaxoSmithKline ($GSK) and sell its animal health business to Eli Lilly ($LLY). Altogether, the transactions are worth more than $25 billion, a decent-sized figure in the scheme of pharma M&A. Even bigger? The changes these deals will wreak at the three companies, Novartis and GSK in particular. Glaxo will be out of the cancer business. Novartis will be out of vaccines and animal health. Together, the two companies will run a consumer health joint venture with a combined $11 billion or so in sales. And Eli Lilly will have an even heftier presence in animal health, where its Elanco unit already boasts major market share. We've taken a look at the different pieces of the three-way deal frenzy in Tuesday's news coverage. Follow the links to find out more. But here are the basics: Why did Glaxo choose to get out of the cancer business, and what does Novartis get for its $16 billion? CEOs Andrew Witty and Joe Jimenez have something to say about that. What does GSK propose to do with Novartis' vaccines business, particularly its meningitis B shot Bexsero? Build scale and add sales in a business that relies on high volumes--advantages worth up to $7.1 billion in up-front and milestone payments. How will Glaxo and Novartis meld their consumer health line-ups and save money in the process? In a joint venture controlled by GSK, with well-known brand names and distribution all over the world. What will Lilly gain in picking up Novartis' animal health business for $5.4 billion? Status as the second-biggest animal health company worldwide, plus a boost to this year's top line, for starters. We have one unanswered question, though. With rumors about Novartis' strategic review swirling for months, an asset swap with GSK never came up. How did these companies keep it quiet? -- Tracy Staton |
» 猜你喜欢
加巴喷丁胶囊激素6月超限杂质结构
已经有4人回复
中药检测种决明子、枳实、水蛭、茯苓品种检测问题交流
已经有2人回复
药理学论文润色/翻译怎么收费?
已经有111人回复
天平合规性问题
已经有113人回复
跪求SIMCA14 安装包
已经有0人回复
多糖提取纯化结构表征和活性
已经有0人回复
求助印度药典2026版 苯酚标准1份
已经有0人回复
东北林业大学徐明 崔亭亭和西安交通大学陈圣华联合培养催化博士
已经有1人回复
英国贝尔法斯特女王大学药物递送方向招CSC博士生
已经有1人回复
Materials Today Chemistry和AMH哪个投稿快啊
已经有0人回复
福州大学李兴淑教授课题组招收2027年博士研究生
已经有3人回复

for5
木虫 (正式写手)
- 应助: 127 (高中生)
- 金币: 3356.6
- 红花: 10
- 帖子: 880
- 在线: 283.6小时
- 虫号: 696070
- 注册: 2009-02-04
- 性别: GG
- 专业: 微生物生理与生物化学

2楼2014-04-23 10:56:01
3楼2014-04-23 11:49:54










回复此楼